Research for treatments, prevention and a cure
DEBUG INFO [ON]
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Prevention and Vulnerable Populations (PVP)


CTN 284: WelTel Retain

Promoting Engagement in Pre-ART HIV Care Through SMS

Print Friendly, PDF & Email

About the study

Patient retention in care (continuing to see their medical professional) and adherence to treatment (following the treatment program) leads to better health outcomes for patients and is important to the success of HIV care programs. Unfortunately, many patients do not consistently remain in care. Furthermore, low-income settings pose extra challenges to maintaining treatment because of increased barriers to access health care.

Cell phones provide new opportunities for communication between medical professionals and their patients. The purpose of this study is to determine if the use of cell phone text-messaging between clinic staff and individuals infected with HIV helps people stay in HIV care.

About the disease/condition

Access to antiretroviral therapy (ART), the most common treatment for HIV, continues to expand throughout sub-Saharan Africa, and research has shown that high levels of patient retention and adherence to treatment programs are very important to the success of HIV care. Yet, after 6 months, over 20% of patients in low-income areas are no longer on consistent treatment, and after 3 years, 35% are no longer on consistent treatment. Retention is even lower for patients who have not yet begun treatment. New communication technologies like cell phones give us new opportunities to develop strategies to improve treatment and communication between medical professionals and patients.

Study Approach

This study will recruit 700 participants who will be followed-up for 12 months. It will take place at two large health centres in Nairobi that offer HIV care and treatment. The clinics serve low-income populations that have minimal access to basic services such as running water, sanitation, and electricity. The participants will be randomly placed into one of two groups.

The first group of patients will use a cell phone to stay in contact with the medical team. The second group will receive standard care. Each group will have the same number of patients. If the use of cell phones is found to be more effective than standard care at retaining patients, the participants in the group receiving standard care will gradually be moved into the other group after the first phase of the study.

Eligibility criteria

Individuals will be eligible for the study if they meet the following inclusion criteria:

Inclusion Criteria

  • evidence of HIV infection
  • undertaking an HIV test at the Kibera Community or Baba Dogo Health Centres
  • own or have sufficient access to a cell phone; able to operate a cell phone using simple text-messaging (or have somebody text message on their behalf)
  • able and willing to provide informed consent to participate

Exclusion Criteria

  • previously taken or currently taking ART
  • previously assessed for ART eligibility
  • pregnant

For more information on inclusion and exclusion criteria, please refer to clinicaltrials.gov.

Participating sites

Kibera Community Health Centre
Nairobi, Kenya

Baba Dogo Health Centre
Nairobi, Kenya

Publication

van der Kop ML, Thabane L, Awiti PO, Muhula S, Kyomuhangi LB, Lester RT, Ekström AM. Advanced HIV disease at presentation to care in Nairobi, Kenya: late diagnosis or delayed linkage to care?-a cross-sectional study. BMC Infect Dis. 2016;16(1):169.

Patel AR, Lester RT, Marra CA, van der Kop ML, Ritvo P, Engel L, Karanja S, Lynd LD. The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya. Health Qual Life Outcomes. 2017;15(1):143.

Additional Information

If you would like more information on this clinical study, please refer to the principal investigator.

Principal Investigators

Dr. Richard Lester, MD
Clinical Assistant Professor, Faculty of Medicine, University of British Columbia
Clinic Physician, BCCDC
655 West 12th Avenue, Vancouver, BC, V5Z 4R4
1.604.707.5606 (office) or
1.604.789.2908 (mobile)

Mr. Samuel Muhula, MSc
Research Programme Manager
AMREF Health Africa
254.20.699.4000

Latest News

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Call for Nominations: Community Advisory Committee (CAC) 2018

| Uncategorized | No Comments

The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…

Guest Blog: Dr. Nadine Kronfli on HCV treatment in Canadian prisons

| Hepatitis C | No Comments

Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….

Guest Blog: CTN Postdoc Dr. Malika Sharma

| Uncategorized | No Comments

CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.

Research for treatments, prevention and a cure